|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Shan-Ney Huang | Chih-Hui Cheng | Chih-Hui Cheng | 02-27031098 | 11F., No.236, Sec. 4, Xinyi Rd., Da' an Dist., Taipei City 106, TaiwanTaipei, Taiwan | 2011/09/23 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Oneness Biotech is dedicated to develop first-in-class and best-in-class new drugs to fulfil unmet medical need in chronic dermatologic and immunological disorders. With the established proprietary platform, Oneness can develop antibodies with high affinity and specificity in an efficient manner and is with full capacity to propel pipeline development from preclinical to clinical stages. Its lead drugs for diabetic foot ulcers has been approved by Taiwan FDA in March 2021 and being launched into the global market. Oneness further drives the pipeline into different clinical stages where 1 botanical new drug is under phase 3 and Fast Track designation in the U.S., 2 antibodies under phase 2 studies and 1 small molecule under phase 1 study. By upholding its business principle to create and share "health, happiness, and love" with commitment in "developing new drugs and caring for life", Oneness continuously takes initiatives to turn innovation into medicines for the benefits of patients. |
Market Information ( 2023/09/22 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
1043.259 | 177.00 | 174.00 | 176.50 | 0.00 | 1239 | 13,022 | 57 | ||||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2023/09/22) |
TPEx measures adopted (2023/09/22) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
![]() |
![]() |
![]() |